8-K Announcements
6Material company update
Mar 19, 2026·SEC
Material company update
Mar 10, 2026·SEC
Material company update
Jan 12, 2026·SEC
SAB Biotherapeutics, Inc.(SABS)Earnings, Financials & Key Ratios
SABS•NASDAQ
$3.80
$181M mkt cap·Price updated May 6, 2026
AboutSAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.Show more
- Revenue$0-100.0%
- EBITDA-$49M-28.4%
- Net Income$13M+138.9%
- EPS (Diluted)-0.79+78.5%
- ROE14.96%+118.3%
- ROIC-43.53%+80.8%
- Debt/Equity0.04-78.2%
SABS Key Insights
SAB Biotherapeutics, Inc. (SABS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SABS Price & Volume
SAB Biotherapeutics, Inc. (SABS) stock price & volume — 10-year historical chart
Loading chart...
SABS Growth Metrics
SAB Biotherapeutics, Inc. (SABS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-7.98%
3 Years-
TTM138.92%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM78.53%
Return on Capital
10 Years-40.46%
5 Years-57.65%
3 Years-65.9%
Last Year-49.36%
SABS Recent Earnings
SAB Biotherapeutics, Inc. (SABS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 1/12 qtrs (20%)
Q2 2026Latest
Mar 9, 2026EPS
$0.46
Est $0.16
-187.5%
Revenue
—
Est $100,000
Q4 2025
Nov 14, 2025EPS
$0.21
Est $0.59
+64.4%
Revenue
—
Est $100,000
Q3 2025
Aug 7, 2025EPS
$1.09
Est $0.82
-32.9%
Revenue
—
Est $83,330
Q2 2025
May 9, 2025EPS
$0.56
Est $1.00
+44.0%
Revenue
—
Est $125,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 9, 2026 | $0.46vs $0.16-187.5% | —vs $100,000 |
| Q4 2025 | Nov 14, 2025 | $0.21vs $0.59+64.4% | —vs $100,000 |
| Q3 2025 | Aug 7, 2025 | $1.09vs $0.82-32.9% | —vs $83,330 |
| Q2 2025 | May 9, 2025 | $0.56vs $1.00+44.0% | —vs $125,000 |
Based on last 12 quarters of dataView full earnings history →
SABS Peer Comparison
SAB Biotherapeutics, Inc. (SABS) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ARGX | 49.97B | 807.55 | 63.19 | 78.6% | 23.34% | 15.14% | 0.01 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 ADMA | 2.46B | 10.08 | 16.80 | 19.63% | 28.8% | 34.98% | 0.17 | |
 CRVS | 1.15B | 15.45 | -29.15 | -23.29% | 0.02 | |||
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 VXRT | 179.17M | 0.75 | 10.64 | 7.27% | 6.88% | 33.83% | 0.10 | |
 NVAX | 1.53B | 9.36 | 3.69 | 64.69% | -14.73% |
Compare SABS vs Peers
SAB Biotherapeutics, Inc. (SABS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SABS Income Statement
SAB Biotherapeutics, Inc. (SABS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 3.44M | 55.24M | 60.88M | 23.9M | 2.24M | 1.32M | 0 |
| Revenue Growth % | - | 1504.82% | 10.21% | -60.73% | -90.63% | -40.94% | -100% |
| Cost of Goods Sold | 0 | 0 | 1.65M | 3.29M | 3.75M | 4.79M | 0 |
| COGS % of Revenue | - | - | 2.72% | 13.77% | 167.26% | 362.41% | - |
| Gross Profit | 3.44M▲ 0% | 55.24M▲ 1504.8% | 59.22M▲ 7.2% | 20.61M▼ 65.2% | -1.51M▼ 107.3% | -3.47M▼ 130.4% | 0▲ 100.0% |
| Gross Margin % | 100% | 100% | 97.28% | 86.23% | -67.26% | -262.41% | - |
| Gross Profit Growth % | - | 1504.82% | 7.21% | -65.2% | -107.31% | -130.42% | 100% |
| Operating Expenses | 12.12M | 34.68M | 72.62M | 49.53M | 36.57M | 39.44M | 48.95M |
| OpEx % of Revenue | 351.98% | 62.78% | 119.28% | 207.2% | 1633.27% | 2982.46% | - |
| Selling, General & Admin | 4.1M | 6.77M | 17.09M | 16.38M | 23.8M | 9.28M | 14.6M |
| SG&A % of Revenue | 119% | 12.26% | 28.07% | 68.54% | 1062.93% | 701.41% | - |
| Research & Development | 8.02M | 27.91M | 57.18M | 36.44M | 16.52M | 30.16M | 34.35M |
| R&D % of Revenue | 233% | 50.52% | 93.94% | 152.44% | 737.61% | 2281.05% | - |
| Other Operating Expenses | -1K | 0 | -1.65M | -3.29M | -3.75M | 0 | 0 |
| Operating Income | -8.67M▲ 0% | 20.56M▲ 337.0% | -13.39M▼ 165.2% | -28.92M▼ 115.9% | -38.08M▼ 31.7% | -42.91M▼ 12.7% | -48.95M▼ 14.1% |
| Operating Margin % | -252% | 37.22% | -22% | -120.98% | -1700.54% | -3244.87% | - |
| Operating Income Growth % | - | 337% | -165.15% | -115.92% | -31.67% | -12.7% | -14.08% |
| EBITDA | -8.35M | 21.11M | -11.74M | -25.63M | -34.33M | -38.12M | -48.95M |
| EBITDA Margin % | -242.61% | 38.21% | -19.28% | -107.2% | -1533.27% | -2882.46% | - |
| EBITDA Growth % | - | 352.74% | -155.62% | -118.3% | -33.97% | -11.03% | -28.43% |
| D&A (Non-Cash Add-back) | 323.41K | 548.18K | 1.65M | 3.29M | 3.75M | 4.79M | 0 |
| EBIT | -8.56M | 20.59M | -16.85M | -18.41M | -41.88M | -33.79M | 0 |
| Net Interest Income | -315K | -443K | -271K | -231K | 269.68K | 967.6K | 0 |
| Interest Income | 113.13K | 26.13K | 23.11K | 71.07K | 584.97K | 1.29M | 1.43M |
| Interest Expense | 428.48K | 469.15K | 294.46K | 301.58K | 315.28K | 318.4K | -240.66K |
| Other Income/Expense | -313K | -439K | -3.75M | 10.2M | -4.12M | 8.81M | 62.23M |
| Pretax Income | -8.99M▲ 0% | 20.12M▲ 323.9% | -17.14M▼ 185.2% | -18.72M▼ 9.2% | -42.19M▼ 125.5% | -34.11M▲ 19.2% | 13.27M▲ 138.9% |
| Pretax Margin % | -261.07% | 36.42% | -28.16% | -78.29% | -1884.5% | -2579.03% | - |
| Income Tax | 0 | 0 | 0 | 25.63K | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | -0.14% | 0% | 0% | 0% |
| Net Income | -8.99M▲ 0% | 20.12M▲ 323.9% | -17.14M▼ 185.2% | -18.74M▼ 9.3% | -42.19M▼ 125.1% | -34.11M▲ 19.2% | 13.27M▲ 138.9% |
| Net Margin % | -261.07% | 36.42% | -28.16% | -78.4% | -1884.5% | -2579.03% | - |
| Net Income Growth % | - | 323.88% | -185.22% | -9.31% | -125.14% | 19.17% | 138.92% |
| Net Income (Continuing) | -8.99M | 20.12M | -17.14M | -18.74M | -42.19M | -34.11M | 13.27M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.22▲ 0% | 7.45▲ 3486.4% | -6.30▼ 184.6% | -4.31▲ 31.6% | -7.64▼ 77.3% | -3.68▲ 51.8% | -0.79▲ 78.5% |
| EPS Growth % | - | 3486.36% | -184.56% | 31.59% | -77.26% | 51.83% | 78.53% |
| EPS (Basic) | -0.22 | 4.63 | -3.94 | -4.31 | -7.64 | -3.68 | 0.22 |
| Diluted Shares Outstanding | 4.35M | 2.7M | 2.73M | 4.35M | 5.52M | 9.26M | 61.34M |
| Basic Shares Outstanding | 4.35M | 4.35M | 4.35M | 4.35M | 5.52M | 9.26M | 19.31M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
SABS Balance Sheet
SAB Biotherapeutics, Inc. (SABS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 9.29M | 34.46M | 50.19M | 22.1M | 58.91M | 23.79M | 101.05M |
| Cash & Short-Term Investments | 6.35M | 12.61M | 33.21M | 15.05M | 56.57M | 20.76M | 96.59M |
| Cash Only | 6.35M | 12.61M | 33.21M | 15.05M | 56.57M | 8.9M | 10.5M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 11.86M | 86.09M |
| Accounts Receivable | 2.82M | 20.57M | 8.01M | 5.56M | 0 | 54.95K | 946.78K |
| Days Sales Outstanding | 298.91 | 135.92 | 48.03 | 84.85 | - | 15.17 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 6.34M | 0 | 0 | 2.98M | 3.51M |
| Total Non-Current Assets | 8.71M | 22.08M | 30.95M | 28.81M | 25.03M | 20.4M | 71.76M |
| Property, Plant & Equipment | 8.71M | 22.08M | 30.95M | 28.34M | 24.68M | 19.92M | 19.4M |
| Fixed Asset Turnover | 0.39x | 2.50x | 1.97x | 0.84x | 0.09x | 0.07x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 46.89M |
| Other Non-Current Assets | 0 | 0 | 0 | 467.69K | 350.23K | 482.1K | 5.46M |
| Total Assets | 18M▲ 0% | 56.54M▲ 214.0% | 81.14M▲ 43.5% | 50.9M▼ 37.3% | 83.94M▲ 64.9% | 44.2M▼ 47.3% | 172.81M▲ 291.0% |
| Asset Turnover | 0.19x | 0.98x | 0.75x | 0.47x | 0.03x | 0.03x | - |
| Asset Growth % | - | 214.04% | 43.52% | -37.26% | 64.9% | -47.35% | 291.01% |
| Total Current Liabilities | 4.62M | 11.06M | 26.46M | 14.99M | 10.81M | 7.98M | 10.68M |
| Accounts Payable | 2.17M | 7.38M | 4.46M | 3.68M | 945.93K | 1.69M | 3.15M |
| Days Payables Outstanding | - | - | 983.89 | 407.92 | 92.19 | 129.07 | - |
| Short-Term Debt | 1.39M | 538.73K | 1.8M | 772.66K | 1.05M | 811.84K | 951.37K |
| Deferred Revenue (Current) | 0 | 100K | 100K | 0 | 1.32M | 0 | 0 |
| Other Current Liabilities | 248.72K | 1.17M | 8.7M | 8.1M | 4.49M | 5.47M | 9.73M |
| Current Ratio | 2.01x | 3.11x | 1.90x | 1.47x | 5.45x | 2.98x | 9.46x |
| Quick Ratio | 2.01x | 3.11x | 1.90x | 1.47x | 5.45x | 2.98x | 9.46x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 15.69M | 6.47M | 16.14M | 4.85M | 15.83M | 10.25M | 10.63M |
| Long-Term Debt | 53.45K | 172.04K | 0 | 541.64K | 0 | 0 | 5M |
| Capital Lease Obligations | 5.64M | 6.3M | 5.42M | 3.99M | 4.05M | 3.86M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 10M | 0 | 10.72M | 320.93K | 11.77M | 6.39M | 5.64M |
| Total Liabilities | 20.31M | 17.53M | 42.59M | 19.85M | 26.64M | 18.23M | 21.32M |
| Total Debt | 7.64M | 8.13M | 8.52M | 5.93M | 5.91M | 4.67M | 5.95M |
| Net Debt | 1.29M | -4.48M | -24.69M | -9.12M | -50.66M | -4.23M | -4.55M |
| Debt / Equity | - | 0.21x | 0.22x | 0.19x | 0.10x | 0.18x | 0.04x |
| Debt / EBITDA | - | 0.39x | - | - | - | - | - |
| Net Debt / EBITDA | - | -0.21x | - | - | - | - | - |
| Interest Coverage | -20.24x | 43.82x | -45.48x | -95.89x | -120.76x | -134.77x | - |
| Total Equity | -2.31M▲ 0% | 39.01M▲ 1791.9% | 38.55M▼ 1.2% | 31.06M▼ 19.4% | 57.3M▲ 84.5% | 25.97M▼ 54.7% | 151.49M▲ 483.4% |
| Equity Growth % | - | 1791.9% | -1.17% | -19.43% | 84.49% | -54.68% | 483.35% |
| Book Value per Share | -0.53 | 14.44 | 14.10 | 7.14 | 10.38 | 2.80 | 2.47 |
| Total Shareholders' Equity | -2.31M | 39.01M | 38.55M | 31.06M | 57.3M | 25.97M | 151.49M |
| Common Stock | 3.52K | 3.52K | 4.35K | 5.09K | 929 | 935 | 4.77K |
| Retained Earnings | -32.1M | -11.98M | -29.13M | -47.87M | -90.06M | -124.17M | -110.9M |
| Treasury Stock | 0 | 0 | 0 | -5.52M | -5.52M | -5.52M | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 26.42K | -135.41K | 186.51K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SABS Cash Flow Statement
SAB Biotherapeutics, Inc. (SABS) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.21M | 10M | 1.99M | -23.46M | -25.12M | -34.29M | -44.78M |
| Operating CF Margin % | -267.71% | 18.11% | 3.26% | -98.14% | -1121.9% | -2593.14% | - |
| Operating CF Growth % | - | 208.58% | -80.14% | -1280.73% | -7.08% | -36.52% | -30.57% |
| Net Income | -8.99M | 20.12M | -17.14M | -18.74M | -42.19M | -34.11M | 13.27M |
| Depreciation & Amortization | 323.41K | 548.18K | 1.65M | 3.29M | 3.75M | 4.79M | 3.08M |
| Stock-Based Compensation | 371.39K | 1.3M | 2.31M | 2.67M | 2.42M | 2.94M | 5.21M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 422 | -2.25K | 3.48M | -10.45M | 8.58M | -5.62M | -66.34M |
| Working Capital Changes | -923.37K | -11.95M | 11.68M | -237.57K | 2.33M | -2.3M | 0 |
| Change in Receivables | -2.56M | -17.75M | 12.56M | 2.45M | 5.56M | -54.95K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.56M | 5.21M | -2.94M | -779.42K | -2.7M | 923.32K | 1.48M |
| Cash from Investing | -608.75K | -12.72M | -10.94M | -2.09M | -152.7K | -11.96M | -121.71M |
| Capital Expenditures | -608.75K | -12.73M | -10.94M | -2.17M | -197.15K | -337.26K | 0 |
| CapEx % of Revenue | 17.69% | 23.05% | 17.98% | 9.06% | 8.81% | 25.5% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 9K | 0 | 76.39K | 44.45K | 0 | -932.66K |
| Cash from Financing | 3.68M | 8.98M | 35.89M | 1.05M | 66.77M | -1.17M | 168.3M |
| Debt Issued (Net) | -623.27K | -917.88K | 1.54M | -1.19M | -390.44K | -907K | 0 |
| Equity Issued (Net) | 1000K | 1000K | 6.75K | 1000K | 1000K | 20.41K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -5.52M | 0 | 0 | 0 |
| Other Financing | 0 | -9.9M | 34.34M | 76.97K | 59.66M | -286.04K | 168.3M |
| Net Change in Cash | -6.14M▲ 0% | 6.26M▲ 202.0% | 26.93M▲ 330.0% | -24.5M▼ 191.0% | 41.52M▲ 269.5% | -47.67M▼ 214.8% | 1.6M▲ 103.4% |
| Free Cash Flow | -9.82M▲ 0% | -2.73M▲ 72.2% | -8.96M▼ 228.5% | -25.63M▼ 186.1% | -25.32M▲ 1.2% | -34.63M▼ 36.8% | -44.78M▼ 29.3% |
| FCF Margin % | -285.39% | -4.94% | -14.71% | -107.2% | -1130.71% | -2618.65% | - |
| FCF Growth % | - | 72.24% | -228.46% | -186.11% | 1.21% | -36.79% | -29.3% |
| FCF per Share | -2.26 | -1.01 | -3.28 | -5.89 | -4.59 | -3.74 | -0.73 |
| FCF Conversion (FCF/Net Income) | 1.03x | 0.50x | -0.12x | 1.25x | 0.60x | 1.01x | -3.37x |
| Interest Paid | 428.48K | 469.15K | 0 | 293.39K | 245.48K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SABS Key Ratios
SAB Biotherapeutics, Inc. (SABS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | 109.63% | -44.21% | -53.85% | -95.51% | -81.92% | 14.96% |
| Return on Invested Capital (ROIC) | - | 92.02% | -41.52% | -121.17% | -199.83% | -226.79% | -43.53% |
| Gross Margin | 100% | 100% | 97.28% | 86.23% | -67.26% | -262.41% | - |
| Net Margin | -261.07% | 36.42% | -28.16% | -78.4% | -1884.5% | -2579.03% | - |
| Debt / Equity | - | 0.21x | 0.22x | 0.19x | 0.10x | 0.18x | 0.04x |
| Interest Coverage | -20.24x | 43.82x | -45.48x | -95.89x | -120.76x | -134.77x | - |
| FCF Conversion | 1.03x | 0.50x | -0.12x | 1.25x | 0.60x | 1.01x | -3.37x |
| Revenue Growth | - | 1504.82% | 10.21% | -60.73% | -90.63% | -40.94% | -100% |
SABS SEC Filings & Documents
SAB Biotherapeutics, Inc. (SABS) SEC filings — annual & quarterly reports (10-K, 10-Q)
SABS Frequently Asked Questions
SAB Biotherapeutics, Inc. (SABS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
SAB Biotherapeutics, Inc. (SABS) saw revenue decline by 100.0% over the past year.
Yes, SAB Biotherapeutics, Inc. (SABS) is profitable, generating $13.3M in net income for fiscal year 2025.
Dividend & Returns
SAB Biotherapeutics, Inc. (SABS) has a return on equity (ROE) of 15.0%. This is reasonable for most industries.
SAB Biotherapeutics, Inc. (SABS) had negative free cash flow of $44.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More SABS
SAB Biotherapeutics, Inc. (SABS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates